Elranatamab (Elrexfio)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses elranatamab (Elrexfio), 40 mg/mL, solution for subcutaneous injection supplied as 76 mg/1.9 mL (40 mg/mL) in a single-dose vial and 44 mg/1.1 mL (40 mg/mL) in a single-dose vial. Indication: For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.